- Home
- CHY vs VIR Comparison
CHY vs VIR Comparison
Compare CHY & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- VIR
- Stock Information
- Founded
- CHY 2003
- VIR 2016
- Country
- CHY United States
- VIR United States
- Employees
- CHY N/A
- VIR N/A
- Industry
- CHY Investment Managers
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- CHY Finance
- VIR Health Care
- Exchange
- CHY Nasdaq
- VIR Nasdaq
- Market Cap
- CHY 792.1M
- VIR 844.9M
- IPO Year
- CHY N/A
- VIR 2019
- Fundamental
- Price
- CHY $10.39
- VIR $4.99
- Analyst Decision
- CHY
- VIR Strong Buy
- Analyst Count
- CHY 0
- VIR 7
- Target Price
- CHY N/A
- VIR $32.86
- AVG Volume (30 Days)
- CHY 128.3K
- VIR 1.6M
- Earning Date
- CHY 01-01-0001
- VIR 05-07-2025
- Dividend Yield
- CHY 10.11%
- VIR N/A
- EPS Growth
- CHY N/A
- VIR N/A
- EPS
- CHY N/A
- VIR N/A
- Revenue
- CHY N/A
- VIR $20,861,000.00
- Revenue This Year
- CHY N/A
- VIR N/A
- Revenue Next Year
- CHY N/A
- VIR $15.32
- P/E Ratio
- CHY N/A
- VIR N/A
- Revenue Growth
- CHY N/A
- VIR N/A
- 52 Week Low
- CHY $9.97
- VIR $4.32
- 52 Week High
- CHY $12.16
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- CHY 54.62
- VIR 44.20
- Support Level
- CHY $10.20
- VIR $4.72
- Resistance Level
- CHY $10.43
- VIR $5.24
- Average True Range (ATR)
- CHY 0.12
- VIR 0.31
- MACD
- CHY -0.02
- VIR 0.08
- Stochastic Oscillator
- CHY 52.70
- VIR 53.74
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.